Clinical trials: Cyclophosphamide, completed
Melanoma
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
The purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate your own immune system to react to your melanoma cells.
- Trial name
- NCT00683670
- Testing
- cyclophosphamide, Mature dendritic cell vaccine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Pennsylvania
HR+/HER2- Early Breast Cancer
A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer
The purpose of this clinical trial is to evaluate the efficacy and safety of Fluzoparib combined with docetaxel in sequential paclitaxel combined with cyclophosphamide for HRD-positive, HR+/HER2- early breast cancer.
- Trial name
- NCT07162051
- Testing
- Fuzaparib, standard chemotherapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Xijing Hospital
Lymphoma
High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma
RATIONALE: Giving high-dose chemotherapy before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or by killing them.
- Trial name
- NCT00544570
- Testing
- filgrastim, carmustine, cyclophosphamide
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia, Higher Risk Myelodysplastic Syndrome
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
This is a phase II trial of nivolumab and low dose cyclophosphamide (CTX) when given in combination to patients with relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS) who are not…
- Trial name
- NCT03417154
- Testing
- Nivolumab, Low dose Cyclophosphamide (CTX) Daily, Low dose Cyclophosphamide (CTX) Every 7 Days
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphoma
Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003631
- Testing
- filgrastim, carboplatin, carmustine
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant
The purpose of this study is to induce anti-myeloma responses in patients with high risk or relapsed myeloma using combination chemo- and immunotherapy comprising sequentially: 1) lymphoid and myeloid suppressive conditioning, 2)…
- Trial name
- NCT00089453
- Testing
- Dexamethasone, Cyclophosphamide, Melphalan
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Leukemia
Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous bone marrow transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002592
- Testing
- c-myb antisense oligonucleotide G4460, filgrastim, busulfan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility
HER-2/neu (+) breast cancer is a more aggressive form of breast cancer. HER-2/neu is a protein that is overproduced by your tumor. It makes your cancer more aggressive.
- Trial name
- NCT00591851
- Testing
- AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002953
- Testing
- cyclophosphamide, epirubicin hydrochloride, paclitaxel
- Where
- 19 sites in South Africa, United Kingdom
- Volunteers
- 704 people
- Sponsor
- Medical Research Council
Lymphoma, Non-Hodgkin, HIV Infections
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide…
- Trial name
- NCT00000801
- Testing
- Filgrastim, Vincristine sulfate, Doxorubicin hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
This phase III trial is studying observation to see how well a risk based treatment strategy works in patients with soft tissue sarcoma.
- Conditions
- Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma
- Trial name
- NCT00346164
- Testing
- doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery
- Where
- 187 sites in United States, Australia and 3 more
- Volunteers
- 588 people
- Sponsor
- Children's Oncology Group
Multiple Myeloma, Myeloma
FT576 in Subjects With Multiple Myeloma
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
- Trial name
- NCT05182073
- Testing
- FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine
- Where
- 14 sites in United States
- Volunteers
- 31 people
- Sponsor
- Fate Therapeutics
Early Breast Cancer
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC)…
- Trial name
- FeDeriCa (NCT03493854)
- Testing
- Cyclophosphamide, Doxorubicin, Docetaxel
- Where
- 107 sites in United States, Argentina and 17 more
- Volunteers
- 500 people
- Sponsor
- Hoffmann-La Roche
Kidney Cancer
Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00003683
- Testing
- doxorubicin hydrochloride, ifosfamide
- Where
- 14 sites in France
- Volunteers
- 40 people
- Sponsor
- UNICANCER
Breast Cancer
Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer
This is an open randomized phase III study. The primary objective of this study is to compare FEC adjuvant chemotherapy in operable breast cancer given either as fixed doses calculated according to the patients surface area or…
- Trial name
- NCT03888677
- Testing
- 5-FU, epirubicin and cyclophosphamide
- Volunteers
- 1,535 people
- Sponsor
- Henrik Lindman
Brain and Central Nervous System Tumors
Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery or radiation therapy may shrink the tumor so that it can be removed…
- Trial name
- NCT00025077
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 50 people
- Sponsor
- Children's Cancer and Leukaemia Group
Breast Cancer
S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combination chemotherapy is more effective with or without filgrastim in treating…
- Trial name
- NCT00016406
- Testing
- filgrastim, cyclophosphamide, doxorubicin
- Where
- 314 sites in United States
- Volunteers
- 399 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
RATIONALE: Chemotherapy may cause early menopause in premenopausal women. Triptorelin may prevent this from happening. PURPOSE: This randomized phase III trial is studying triptorelin to see how well it works in preventing early…
- Trial name
- NCT00311636
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- 18 sites in Italy
- Volunteers
- 280 people
- Sponsor
- Gruppo Italiano Mammella (GIM)
Leukemia, Lymphoma
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
RATIONALE: Giving chemotherapy, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood transplant helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00602693
- Testing
- umbilical cord blood transplantation, Allopurinol, fludarabine phosphate
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Kidney Transplantation, Kidney Failure, Chronic
Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
In small initial studies, combined kidney and bone marrow transplants from the same donor have permitted some individuals to stop taking anti-rejection medicines without rejecting their transplant.
- Trial name
- NCT00801632
- Testing
- Kidney Transplantation, Bone marrow transplantation, MEDI-507
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.